US Department of Defense awards $2.2 M CDN research contract toTwinstrand Therapeutics Inc.
Development of medical countermeasure to ricin
Dr. Thor Borgford, Twinstrand President & CEO, commented "This award is an important recognition of Twinstrand's growing clinical and drug development capabilities. Importantly, we expect the program will lead the company to a significant product opportunity. It is worth noting further that Twinstrand is able to leverage pre-existing therapeutic assets in the development of the countermeasure that make the program an ideal complement to our oncology drug platform."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.